Australia's most trusted source of pharma news
Earlier
Roche's Ocrevus lonely Feb listing
Posted 25 January 2018
Roche's multiple sclerosis (MS) drug Ocrevus will be added to the PBS next week following its recommendation last July.
The drug was the only one to make it onto the PBS for February, and will be listed for the treatment of people with relapsing remitting MS.
Last July the drug won recommendation on its first go with the PBAC on a cost-minimisation basis with Novartis' Gilenya.
"The PBAC anticipated that [Ocrevus] is likely to substitute for all currently PBS listed medicines for relapsing/refractory MS," the committee said in the July outcomes.
Hoping for a repeat of its first success, Roche brought the drug back to the PBAC at its November meeting for reimbursement in primary progressive MS, only to have this application rejected by the committee.
Ocrevus was added to the ARTG last July, four months after its US green light. It was approved this month in Europe.
Yajun Ma
Posted 25 January 2018
Roche's multiple sclerosis (MS) drug Ocrevus will be added to the PBS next week following its recommendation last July.
The drug was the only one to make it onto the PBS for February, and will be listed for the treatment of people with relapsing remitting MS.
Last July the drug won recommendation on its first go with the PBAC on a cost-minimisation basis with Novartis' Gilenya.
"The PBAC anticipated that [Ocrevus] is likely to substitute for all currently PBS listed medicines for relapsing/refractory MS," the committee said in the July outcomes.
Hoping for a repeat of its first success, Roche brought the drug back to the PBAC at its November meeting for reimbursement in primary progressive MS, only to have this application rejected by the committee.
Ocrevus was added to the ARTG last July, four months after its US green light. It was approved this month in Europe.
Yajun Ma
Drought, fire and now virus cut chance of PBS relief.
Don't do it for the accolades; do it for your kids.
New forms of rotavirus vaccine Rotarix.